Covington & Burling has represented Tokyo-based Astellas Pharma on its $3 billion acquisition of U.S. drugmaker Audentes Therapeutics, which was advised by Fenwick & West.

According to Reuters, the acquisition marks the second biggest on record for Astellas after its 2010 purchase of OSI Pharmaceuticals Inc for $3.8 billion. Astellas expects the deal, which is subject to regulatory approval, including U.S. antitrust clearance, to close in the first quarter of 2020.

Reuters added that this sale was a push by Astellas Pharma to make genetic medicines a key area of growth. Gene therapies are one of the hottest areas of drug research and Astellas is offering $60 per share in cash for San Francisco-based Audentes.

Morgan Stanley and Centerview Partners are acting as financial advisors to Astellas and Audentes, respectively.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

White & Case guides TotalEnergies on $903 mln purchase of stake in Malaysia’s SapuraOMV

by Mari Iwata |

White & Case has advised French energy group TotalEnergies on its $903 million acquisition of a 50 percent stake in Malaysia-headquartered SapuraOMV from Austrian oil and gas company OMV.

MoFo, Paul Weiss acting on Japan homebuilder Sekisui’s $4.9 bln purchase of MDC

by Mari Iwata |

Morrison Foerster is advising Japanese homebuilder Sekisui House on its $4.9 billion acquisition of Denver-based MDC Holdings, which was represented by Paul, Weiss, Rifkind, Wharton & Garrison and Brownstein Hyatt Farber Schreck.

Ropes & Gray, Milbank, Wachtell act on Nippon Steel’s $15 bln purchase of U.S. Steel

by Mari Iwata |

U.S. law firm Ropes & Gray has advised Japan’s largest steelmaker Nippon Steel Corporation on its $14.9 billion acquisition of U.S. Steel, which was represented by Milbank and Wachtell, Lipton, Rosen & Katz.